Immune checkpoint inhibitors (ICIs), which target programmed cell death protein-1 (PD-1) or its ligand PD-L1, have yielded durable responses and marked clinical benefits in a subset of patients with diverse cancers [1]. The gene discussed is PDCD1; the disease is cancer.